Deep brain stimulation: A novel strategy for treating Alzheimer's disease

Innovations in Clinical Neuroscience

Volumn 9, Issue 11-12, 2012, Pages 10-17

  Lyketsos, Constantine G ^a   Targum, Steven D ^a,b,c,d,e,f   Pendergrass, Jo Cara ^g   Lozano, Andres M ^h  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Methylation Sciences Inc   (Canada)

^c BrainCells Inc   (United States)

^d Functional Neuromodulation Inc   (United States)

^e Prana Biotechnology Ltd

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Alzheimer's disease; Deep brain stimulation; Fornix; Hippocampus; Neuronal circuitry

Indexed keywords

CORTICOSTERONE;

ALZHEIMER DISEASE; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN FORNIX; BRAIN FUNCTION; DISEASE ASSOCIATION; ELECTROENCEPHALOGRAM; HIPPOCAMPUS; HUMAN; MEDICAL RESEARCH; MEMORY; MEMORY DISORDER; NERVOUS SYSTEM DEVELOPMENT; NEUROIMAGING; NEUROSURGERY; NONHUMAN; OUTCOME ASSESSMENT; TREATMENT DURATION;

EID: 84874290750     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Wimo A, Prince M. Alzheimer's Disease International: World Alzheimer Report 2010: The Global Economic Impact of Dementia. London, United Kingdom: Alzheimer's Disease International (ADI); 2010.
2. Hardy JA, Selkoe D. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 19; 297(5580):353-356.
3. Lyketsos CG, Szekely CA, Mielke MM, et al. Developing new treatments for alzheimer's disease: The who, what, when, and how of biomarker-guided therapies. Int Psychogeriatr. 2008; 20(5):871-889.
4. Neugroschl J, Sano M. An update on treatment and prevention strategies for alzheimer's disease. Curr Neurol Neurosci Rep. 2009;9(5):368-376.
5. Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in alzheimer's disease: the need for a paradigm shift. Neuron. 2011;69(2):203-213.
6. Morgan D. Immunotherapy for alzheimer's disease. J Intern Med. 2011;269(1):54-63.
7. Aisen PS, Saumier D, Briand R, et al. A phase II study targeting amyloid-beta with 3APS in mild-to-moderate alzheimer disease. Neurology. 2006; 67(10):1757-1763.
8. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate alzheimer disease. Neurology. 2009; 73(24):2061-2070.
9. Doody RS, Gavrilova SI, Sano M, Dimebon investigators, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372(9634):207-215.
10. Green RC, Schneider LS, Amato DA, Tarenflurbil Phase 3 Study Group, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild alzheimer disease: a randomized controlled trial. JAMA. 2009;302(23):2557-2564.
11. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008; 372 (9634):216-223.
12. Laxton AW, Tang-Wai DF, McAndrews MP, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol. 2010;68:521-534.
13. Sperling RA, Dickerson BC, Pihlajamaki M, et al. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med. 2010;12(1):27-43.
14. Andrews-Hanna JR, Snyder AZ, Vincent JL, et al. Disruption of large-scale brain systems in advanced aging. Neuron. 2007;56(5):924-935.
15. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63(2):178-188.
16. Raichle ME, MacLeod AM, Snyder AZ, et al. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98(2):676-682.
17. Miller SL, Celone K, DePeau K, et al. Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proc Natl Acad Sci U S A. 2008;105(6):2181-2186.
18. Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic functional connectivity: Mapping, assessment of stability, and relation to alzheimer's disease. J Neurosci. 2009;29(6):1860-1873.
19. Seeley WW, Crawford RK, Zhou J, et al. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62(1):42-52.
20. Smith GS, de Leon MJ, George AE, et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in alzheimer's disease. pathophysiologic implications. Arch Neurol. 1992;49(11):1142-1150.
21. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early alzheimer's disease. Ann Neurol. 1997 Jul;42(1):85-94.
22. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752-758.
23. Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo. Behaviour Neurol. 2009;21(1):117-128.
24. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709-7717.
25. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(Pt 5):1310-1323.
26. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in alzheimer's disease with pittsburgh compound-B. Ann Neurol. 2004;55(3):306-319.
27. Fripp J, Bourgeat P, Acosta O, et al. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage. 2008; 43(3):430-439.
28. Petersen RC, Jack CR, Jr. Imaging and biomarkers in early alzheimer's disease and mild cognitive impairment. Clin Pharmacol Ther. 2009;86(4):438-441.
29. Risacher SL, Saykin AJ, West JD, Alzheimer's Disease Neuroimaging Initiative (ADNI), et al. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res. 2009;6(4):347-361.
30. Powell, TP, Guillery, RW, Cowan WM. A quantitative study of the fornixmamillo-thalamic system. J Anat. 1957;91(4):419-437.
31. Tsivilis D, Vann SD, Denby C, et al. A disproportionate role for the fornix and mammillary bodies in recall versus recognition memory. Nat Neurosci. 2008;11(7):834-842.
32. Wilson CR, Baxter MG, Easton A, Gaffan D. Addition of fornix transection to frontal-temporal disconnection increases the impairment in object-in-place memory in macaque monkeys. Eur J Neurosci. 2008;27(7):1814-1822.
33. Browning PG, Gaffan D, Croxson PL, Baxter MG. Severe scene learning impairment, but intact recognition memory, after cholinergic depletion of inferotemporal cortex followed by fornix transection. Cereb Cortex. 2010;20(2):282-293.
34. Mielke M, Okonkwo O, Oishi K, et al. Fornix integrity and hippocampal volume predict memory decline and progression to AD. Alz Demen. In Press.
35. Mielke MM, Kozauer NA, Chan KC, et al. Regionally-specific diffusion tensor imaging in mild cognitive impairment and alzheimer's disease. Neuroimage. 2009;46(1):47-55.
36. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011;68:165.
37. Sankar T, Tierney TS, Hamani C. Novel applications of deep brain stimulation. Surg Neurol Int. 2012;3:26.
38. Lozano AM. Deep brain stimulation therapy. Br Med J. 2012;344:e1100
39. Moro E, Lang AE, Strafella AP, et al. Bilateral globus pallidus stimulation for huntington's disease. Ann Neurol. 2004;56(2):290-294.
40. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651-660.
41. Medtronic. Parkinson's disease. http://www.medtronic.com/patients/parkinsons-disease/index.htm. Accessed Dec 1, 2012.
42. Oh MY, Seong KH, Abosch A, et al. Long-term hardware-related complications of deep brain stimulation. Neurosurgery. 2002; 50:1268-1276.
43. Toda H, Hamani C, Fawcett AP, et al. The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. J Neurosurg. 2008;108(1):132-138.
44. Hamani C, Stone SS, Garten A, et al. Memory rescue and enhanced neurogenesis following electrical stimulation of the anterior thalamus in rats treated with corticosterone. Exp Neurol. 2011; 232(1):100-104.
45. Stone SS, Teixeira CM, Devito LM, et al. Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. J Neurosci. 2011;31(38):13469-13484.
46. Laxton AW, Tang-Wai DF, McAndrews MP, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol. 2010;68(4):521-534.
47. Alexander GE, Chen K, Pietrini P, et al. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159(5):738-745.
48. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101(13):4637-4642.
49. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: Anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1-38.
50. Ito K, Ahadieh S, Corrigan B, Alzheimer's Disease Working Group, et al. Disease progression meta-analysis model in alzheimer's disease. Alzheimers Dement. 2010;6(1):39-53.
51. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994;151(3):390-396.